AI Chatbot-Enabled ePRO Symptom Monitoring and Self-Management for Early Cardiovascular-Kidney-Metabolic Syndrome

Starting soon · Not applicable

Conditions studied: Cardiovascular Kidney Metabolic Syndrome

In brief

This randomized clinical trial aims to evaluate whether an AI chatbot-enabled, nurse-led electronic patient-reported outcome (ePRO) intervention can improve symptom management and self-care in adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. The study will also assess the safety and feasibility of the intervention. Researchers will investigate whether the program reduces symptom burden, improves patient activation and health literacy, and lowers healthcare utilization such as emergency department visits and hospitalizations compared with usual ePRO monitoring alone. A total of 72 participants will be randomly assigned to either an intervention group, which receives weekly AI chatbot-supported symptom monitoring combined with nurse-led feedback and self-management support, or a control group receiving ePRO monitoring without feedback. Participants will complete PROMIS-29 assessments weekly and attend study evaluations at baseline, 3 months, and 6 months, while clinical outcomes and healthcare use are tracked through electronic medical records.

Key facts

Study ID

NCT07577284

Run by

Taipei Medical University

People needed

72

Starts

2026-05-30

Expected to finish

2029-07-31

Last updated by the study team

2026-05-11

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥40 years
• Classified as having stage CKM syndrome (stage 1-2)
• Receiving outpatient care
• Able to communicate in Mandarin/Taiwanese, and
• Having access to a smartphone/tablet

You may not qualify if…

• End-stage kidney disease requiring dialysis or are listed for kidney transplantation
• Have terminal illness (<6 months life expectancy)
• Have significant cognitive impairment
• Currently enrolled in another interventional study targeting cardiovascular-kidney-metabolic syndrome or multimorbidity

Where it is running

• Taipei Medical University — Taipei, No. 250號, Wuxing St, Xinyi District, Taipei City, 110, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.